Cardiology Letters 2021, 30(5):246-249
COVID-19 in patients with pulmonary arterial hypertension. Analysis after the second pandemic wave in Slovakia.
- 1 Kardiologická klinika LFUK a NÚSCH, a. s., Centrum pre liečbu PAH, Bratislava
- 2 Stredoslovenského ústav srdcových a cievnych chorôb, a. s., Banská Bystrica
- 3 Východoslovenský ústav srdcových a cievnych chorôb, a. s., Koąice
- 4 Detského kardiocentra, NÚSCH, a. s., Bratislava, Slovenská republika
Background: A pandemic caused by a new coronavirus particularly threatens the high risk groups of patients, incuding those with pulmonary arterial hypertension. We evaluated the occurrence of COVID-19 in the group of patients with pulmonary arterial hypertension (PAH), course of disease, mortality and the attitude of patients to vaccination. Data collection. During the period of two weeks before May 15th 2021 we collected, by analysis of documentation and telephone survey, data on adult patients managed from 01.03. 2020 to 15.05.2021 in 3 centers for PAH and the Children's Cardiac Centre. Information on deceased patients was provided by medical staff from the particular PAH centre.
Results: Out of the total number of 168 adult patients (mean age of 54 ± 22 years, 121 females) 32 (19%) had COVID-19 infection during the first or second wave of the epidemic in Slovakia. During this time period 12 patients died and 1 one lung transplantation was performed. 3 of the 12 patients who died suffered from COVID-19 infection. Of the 32 patients infected 7 (21%) were hospitalized, 10 needed oxygen, one artifitial ventilation, and 3 (9%) patients died. Only 74 (47.7%) were vaccinated to date of data collection, although the availability of vaccination for this group of patients was not limited.
Conclusion: Despite the fact that PAH is a severe lung and heart disease with a poor prognosis, the course of the disease and mortality were better than could be expected. Results are limited by low patient numbers, but 6% mortality in people with a mean age of 54 years may still be considered high. Vaccination is low despite good access to the vaccine and clear recommendations.
Keywords: pulmonary arterial hypertension; COVID-19; frequency; mortality; vaccination
Published: May 1, 2021 Show citation
| ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- https://www.who.int/health-topics/coronavirus
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-1242.
Go to original source... - Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020,323:1775-1776.
Go to original source... - Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J. 2015;46:903-975.
Go to original source... - Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-1436.
Go to original source... - Nuche J, Segura de la Cal T, Guarch CJL, et al. Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension. Diagnostic (Basel). 2020;10:548.
Go to original source... - https://korona.gov.sk/koronavirus-na-slovensku-v-cislach
- https://onemocneni-aktualne.mzcr.cz/covid-19
- Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19. In https://ClinicalTrials.gov/show/NCT04287686.
- Zhang F, Chen A, Pan Y, et al. Research Progress on Pulmonary Arterial Hypertension and the Role of the Angiotensin Converting Enzyme 2-Angiotensin-(1-7)-Mas Axis in Pulmonary Arterial Hypertension. Cardiovasc Drugs Ther. 2021;Jan 4:1-8.
Go to original source... - Pérez-Vizcaíno F. Lung ACE2 and ADAM17 in pulmonary arterial hypertension: Implications for COVID-19? J Heart Lung Transplant. 2020;39:1167-1169.
Go to original source... - Malikova E, Galkova K, Vavrinec P, et al. Local and systemic reninangiotensin system participates in cardiopulmonary-renal interactions in monocrotaline-induced pulmonary hypertension in the rat. Mol Cell Biochem 2016;418:147-157.
Go to original source... - Sulica R, Cefali F, Motschwiller C, et al. COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City. Diagnostic (Basel). 2021;11:128.
Go to original source... - Segura de la Cal T, Nuche J, Jiménez López-Guarch C. COVID-19 Experience and Pulmonary Arterial Hypertension: Do Earlier Theses and New Data Still Match? Ann Am Thorac Soc. 2021;18:1080-1081.
Go to original source... - Isidori AM, Giannetta E, Pofi R, et al. Targeting the NOcGMP-PDE5 pathway in COVID-19 infection. Andrology. 2021;9:33-38.
Go to original source...

